For Immuno - Oncology – Programmed Death-Ligand 1 (PD-L1) Expression
Programmed Cell Death Ligand-1 expression or PD-L1 is an important cancer biomarker and has become a critical part of patient engagement for immunotherapy. The targeted blockade of PD-L1 may help to restore the antitumor response.
Development of the combined positive score (CPS) for the evaluation of PD-L1 in solid tumors has indicated that PD-L1 expression on both tumor and tumor-associated immune cells is associated with clinical outcome
OptraSCAN’s PD-L1 automated image analysis (for research use) supports interpretation of PD-L1 IHC expression on both tumor and immune cells in solid tumors. It determines PD-L1 expression on tumor and immune cells showing partial or complete membrane staining on tumor cells along with membrane and/or cytoplasmic staining on immune cells in a single read. It is reliable and can be used to assess PD- L1 expression in a more objective manner.